Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2010

01-07-2010 | Epidemiology

No association between CYP17 T-34C polymorphism and breast cancer risk: a meta-analysis involving 58,814 subjects

Authors: Lei Yao, Fang Fang, Qi Wu, Zhen Yang, Yang Zhong, Long Yu

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Login to get access

Abstract

Breast cancer is one of the most common malignant tumors worldwide. To date, many articles have evaluated the association between Cytochrome P450c17 (CYP17) T-34C polymorphism and breast cancer risk. However, the results remain inconclusive. In order to derive a more precise estimation of the association, a meta-analysis was performed in this study. By searching Medline, ISI Web of Knowledge, Cochrane, ScienceDirect, EBSCO, CNKI, and SinoMed databases, 43 studies including 26,008 cases and 32,806 controls were collected for CYP17 T-34C polymorphism. Crude ORs with 95% CIs were used to assess the strength of association between CYP17 T-34C polymorphism and breast cancer risk. The pooled ORs were performed for codominant model, dominant model, and recessive model, respectively. Overall, no significant associations between CYP17 T-34C polymorphism and breast cancer susceptibility were found for TT versus CC (OR = 0.96; 95% CI: 0.89–1.05), TC versus CC (OR = 0.97; 95% CI: 0.89–1.06), TT + TC versus CC (OR = 0.97; 95% CI: 0.89–1.05) and TT versus TC + CC (OR = 0.98; 95% CI: 0.93–1.03). In the stratified analysis by ethnicity, menopausal status, and sources of controls, significant associations were still not detected in all genetic models. In conclusion, this meta-analysis strongly suggests that CYP17 T-34C polymorphism is not associated with breast cancer risk.
Literature
1.
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics 2002. CA Cancer J Clin 55:74–108CrossRefPubMed
2.
Lichtenstein P, Holm NV, Verkasalo PK (2000) Environmental and heritable factors in the causation of cancer. N Engl J Med 343:78–85CrossRefPubMed
3.
Dunning AM, Healey CS, Pharoah PDP, Teare MD, Ponder BAJ, Easton DF (1999) A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 8:843–854PubMed
4.
Picado-Leonard J, Miller WL (1987) Cloning and sequencing of the human gene for P450c17 (steroid 17α-hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA 6:439–448CrossRefPubMed
5.
Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R (1994) Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 3:1873–1876CrossRefPubMed
6.
Kadonaga JT, Jones KA, Tjian R (1986) Promoter-specific activation of RNA polymerase-II transcription by Sp1. Trends Biochem Sci 11:20–23CrossRef
7.
Nandi S, Guzman RC, Yang J (1995) Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci USA 92:3650–3657CrossRefPubMed
8.
Jefcoate CR, Liehr JG, Santen RJ, Sutter TR, Yager JD, Yue W, Santner SJ, Tekmal R, Demers L, Pauley R, Naftolin F, Mor G, Berstein L (2000) Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr 27:95–112PubMed
9.
Dunning AM, Healey CS, Pharoah PD, Foster NA, Lipscombe JM, Redman KL, Easton DF, Day NE, Ponder BA (1998) No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br J Cancer 77:2045–2047PubMed
10.
Helzlsouer KJ, Huang HY, Strickland PT, Hoffman S, Alberg AJ, Comstock GW, Bell DA (1998) Association between CYP17 polymorphisms and the development of breast cancer. Cancer Epidemiol Biomarkers Prev 7:945–949PubMed
11.
Weston A, Pan CF, Bleiweiss IJ, Ksieski HB, Roy N, Maloney N, Wolff MS (1998) CYP17 genotype and breast cancer risk. Cancer Epidemiol Biomarkers Prev 7:941–944PubMed
12.
Bergman-Jungeström M, Gentile M, Lundin AC, Wingren S (1999) Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int J Cancer 84:350–353CrossRefPubMed
13.
Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Kelsey KT, Hunter DJ (1999) The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 59:1015–1020PubMed
14.
Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY (1999) Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 59:4870–4875PubMed
15.
Kristensen NV, Haraldsen EK, Anderson KB, Lønning PE, Erikstein B, Kåresen R, Gabrielsen OS, Børresen-Dale AL (1999) CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res 59:2825–2828
16.
Young IE, Kurian KM, Annink C, Kunkler IH, Anderson VA, Cohen BB, Hooper ML, Wyllie AH, Steel CM (1999) A polymorphism in the CYP17 gene is associated with male breast cancer. Br J Cancer 81:141–143CrossRefPubMed
17.
Hamajima N, Iwata H, Obata Y, Matsuo K, Mizutani M, Iwase T, Miura S, Okuma K, Ohashi K, Tajima K (2000) No association of the 5′ promoter region polymorphism of CYP17 with breast cancer risk in Japan. Jpn J Cancer Res 91:880–885PubMed
18.
Kuligina ES, Togo AV, Suspitsin EN, Grigoriev MY, Pozharisskiy KM, Chagunava OL, Berstein LM, Theillet C, Hanson KP, Imyanitov EN (2000) CYP17 polymorphism in the groups of distinct breast cancer susceptibility: comparison of patients with the bilateral disease vs. monolateral breast cancer patients vs. middle-aged female controls vs. elderly tumor-free women. Cancer Lett 156:45–50CrossRefPubMed
19.
Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Vainio H, Uusitupa M, Hirvonen A (2000) Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. Cancer Epidemiol Biomarkers Prev 9:1343–1348PubMed
20.
Feigelson HS, McKean-Cowdin R, Coetzee GA, Stram DO, Kolonel LN, Henderson BE (2001) Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res 61:785–789PubMed
21.
Ambrosone CB, Moysich KB, Furberg H, Freudenheim JL, Bowman ED, Ahmed S, Graham S, Vena JE, Shields PG (2003) CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors. Breast Cancer Res 5:R45–R51CrossRefPubMed
22.
Gudmundsdottir K, Thorlacius S, Jonasson JG, Sigfusson BF, Tryggvadottir L, Eyfjord JE (2003) CYP17 promoter polymorphism and breast cancer risk in males and females in relation to BRCA2 status. Br J Cancer 88:933–936CrossRefPubMed
23.
Tan W, Qi J, Xing DY, Miao XP, Pan KF, Zhang L, Lin DX (2003) Relation between single nucleotide polymorphism in estrogen-metabolizing genes COMT, CYP17 and breast cancer risk among Chinese women. Zhonghua Zhong Liu Za Zhi 25:453–456PubMed
24.
Wu AH, Seow A, Arakawa K, Van Den Berg D, Lee HP, Yu MC (2003) HSD17B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore. Int J Cancer 104:450–457CrossRefPubMed
25.
Ahsan H, Whittemore AS, Chen Y, Senie RT, Hamilton SP, Wang Q, Gurvich I, Santella RM (2004) Variants in estrogen-biosynthesis genes CYP17 and CYP19 and breast cancer risk: a family-based genetic association study. Breast Cancer Res 7:R71–R81CrossRefPubMed
26.
Chacko P, Rajan B, Mathew BS, Joseph T, Pillai MR (2004) CYP17 and SULT1A1 gene polymorphisms in Indian breast cancer. Breast Cancer 11:380–388CrossRefPubMed
27.
Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, Novik KL, Kelemen L, Ogata S, Pharoah PD, Easton DF, Day NE, Ponder BA (2004) Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 96:936–945PubMedCrossRef
28.
Hefler LA, Tempfer CB, Grimm C, Lebrecht A, Ulbrich E, Heinze G, Leodolter S, Schneeberger C, Mueller MW, Muendlein A, Koelbl H (2004) Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women. Cancer 101:264–269CrossRefPubMed
29.
Aston CE, Ralph DA, Lalo DP, Manjeshwar S, Gramling BA, DeFreese DC, West AD, Branam DE, Thompson LF, Craft MA, Mitchell DS, Shimasaki CD, Mulvihill JJ, Jupe ER (2005) Oligogenic combinations associated with breast cancer risk in women under 53 years of age. Hum Genet 116:208–221CrossRefPubMed
30.
Einarsdóttir K, Rylander-Rudqvist T, Humphreys K, Ahlberg S, Jonasdottir G, Weiderpass E, Chia KS, Ingelman-Sundberg M, Persson I, Liu J, Hall P, Wedrén S (2005) CYP17 gene polymorphism in relation to breast cancer risk: a case-control study. Breast Cancer Res 7:R890–R896CrossRefPubMed
31.
Han DF, Zhou X, Hu MB, Xie W, Mao ZF, Chen DE, Liu F, Zheng F (2005) Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study. Chin Med J (Engl) 118:1507–1516
32.
Hopper JL, Hayes VM, Spurdle AB, Chenevix-Trench G, Jenkins MA, Milne RL, Dite GS, Tesoriero AA, McCredie MR, Giles GG, Southey MC (2005) A protein-truncating mutation in CYP17A1 in three sisters with early-onset breast cancer. Hum Mutat 26:298–302CrossRefPubMed
33.
Onland-Moret NC, van Gils CH, Roest M, Grobbee DE, Peeters PH (2005) Cyp17, urinary sex steroid levels and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev 14:815–820CrossRefPubMed
34.
Shin MH, Lee KM, Yang JH, Nam SJ, Kim JW, Yoo KY, Park SK, Noh DY, Ahn SH, Kim B, Kang D (2005) Genetic polymorphism of CYP17 and breast cancer risk in Korean women. Exp Mol Med 37:11–17PubMed
35.
Piller R, Verla-Tebit E, Wang-Gohrke S, Linseisen J, Chang-Claude J (2006) CYP17 genotype modifies the association between lignan supply and premenopausal breast cancer risk in humans. J Nutr 136:1596–1603PubMed
36.
Chakraborty A, Murthy NS, Chintamani C, Bhatnagar D, Mohil RS, Sharma PC, Saxena S (2007) CYP17 gene polymorphism and its association with high-risk north Indian breast cancer patients. J Hum Genet 52:159–165CrossRefPubMed
37.
Setiawan VW, Schumacher FR, Haiman CA, Stram DO, Albanes D, Altshuler D, Berglund G, Buring J, Calle EE, Clavel-Chapelon F, Cox DG, Gaziano JM, Hankinson SE, Hayes RB, Henderson BE, Hirschhorn J, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Ma J, Le Marchand L, Linseisen J, Lund E, Navarro C, Overvad K, Palli D, Peeters PH, Pike MC, Riboli E, Stampfer MJ, Thun MJ, Travis R, Trichopoulos D, Yeager M, Ziegler RG, Feigelson SH, Chanock SJ (2007) CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev 16:2237–2246CrossRefPubMed
38.
Xie W, Feng MH, Wang FB, Cheng TT, Hu MB, Gong LL (2007) Correlation of polymorphism in estrogen metabolizing genes CYP17 and estrogen exposure and its relation with breast cancer susceptibility. Med J Wuhan Univ 28:446–449
39.
Chen Y, Gammon MD, Teitelbaum SL, Britton JA, Terry MB, Shantakumar S, Eng SM, Wang Q, Gurvich I, Neugut AI, Santella RM, Ahsan H (2008) Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: results from the Long Island Breast Cancer Study Project. Carcinogenesis 29:766–771CrossRefPubMed
40.
Sakoda LC, Blackston C, Doherty JA, Ray RM, Lin MG, Stalsberg H, Gao DL, Feng Z, Thomas DB, Chen C (2008) Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women. Cancer Epidemiol Biomarkers Prev 17:1066–1073CrossRefPubMed
41.
Antognelli C, Del Buono C, Ludovini V, Gori S, Talesa VN, Crinò L, Barberini F, Rulli A (2009) CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study. BMC Cancer 9:115CrossRefPubMed
42.
Hosseini M, Houshmand M, Ebrahimi A (2009) Breast cancer risk not only was not associated with CYP17 A2 allele but also was related to A1 allele. Arch Med Sci 5:103–106
43.
Jakubowska A, Gronwald J, Menkiszak J, Górski B, Huzarski T, Byrski T, Tołoczko-Grabarek A, Gilbert M, Edler L, Zapatka M, Eils R, Lubiński J, Scott RJ, Hamann U (2009) BRCA1-associated breast and ovarian cancer risks in Poland no association with commonly studied polymorphisms. Breast Cancer Res Treat. doi: 10.​1007/​s10549-009-0390-5
44.
Kato I, Cichon M, Yee CL, Land S, Korczak JF (2009) African American-preponderant single nucleotide polymorphisms (SNPs) and risk of breast cancer. Cancer Epidemiol 33:24–30CrossRefPubMed
45.
The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk (2009) Postmenopausal estrogen monotherapy-associated breast cancer risk is modified by CYP17A1_-34_T>C polymorphism. Breast Cancer Res Treat. doi: 10.​1007/​s10549-009-0490-2
46.
Samson M, Rama R, Swaminathan R, Sridevi V, Nancy KN, Rajkumar T (2009) CYP17 (T34C), CYP19 (Trp39Arg), and FGFR2 (C906T) polymorphisms and the risk of breast cancer in south Indian women. Asian Pac J Cancer Prev 10:111–114PubMed
47.
Sangrajrang S, Sato Y, Sakamoto H, Ohnami S, Laird NM, Khuhaprema T, Brennan P, Boffetta P, Yoshida T (2009) Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. Int J Cancer 125:837–843CrossRefPubMed
48.
Syamala VS, Syamala V, Sheeja VR, Kuttan R, Balakrishnan R, Ankathil R (2009) Possible Risk Modification by Polymorphisms of Estrogen Metabolizing Genes in Familial Breast Cancer Susceptibility in an Indian Population. Cancer Invest. doi: 10.​3109/​0735790090274449​4
49.
Zhang L, Gu L, Qian B, Hao X, Zhang W, Wei Q, Chen K (2009) Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women. Breast Cancer Res Treat 114:327–338CrossRefPubMed
50.
Spurdle AB, Hopper JL, Dite GS, Chen X, Cui J, McCredie MR, Giles GG, Southey MC, Venter DJ, Easton DF, Chenevix-Trench G (2000) CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst 92:1674–1681CrossRefPubMed
51.
McCann SE, Moysich KB, Freudenheim JL, Ambrosone CB, Shields PG (2002) The risk of breast cancer associated with dietary lignans differs by CYP17 genotype in women. J Nutr 132:3036–3041PubMed
52.
Cui JS, Spurdle AB, Southey MC, Dite GS, Venter DJ, McCredie MR, Giles GG, Chenevix-Trench G, Hopper JL (2003) Regressive logistic and proportional hazards disease models for within-family analyses of measured genotypes, with application to a CYP17 polymorphism and breast cancer. Genet Epidemiol 24:161–172CrossRefPubMed
53.
Verla-Tebit E, Wang-Gohrke S, Chang-Claude J (2005) CYP17 5′-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study. Breast Cancer Res 7:R455–R464CrossRefPubMed
54.
Chang JH, Gertig DM, Chen X, Dite GS, Jenkins MA, Milne RL, Southey MC, McCredie MR, Giles GG, Chenevix-Trench G, Hopper JL, Spurdle AB (2005) CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors Australian Breast Cancer Family Study. Breast Cancer Res 7:R513–R521CrossRefPubMed
55.
Hu MB, Xie W, Xiong B, Han DF, Li Y, Feng MH, Zhou YF (2006) Study on the relationship between polymorphisms of genes (CYP17, CYP19 and SULT1A1) and susceptibility to breast cancer in Chinese women. Zhonghua Liu Xing Bing Xue Za Zhi 27:351–355PubMed
56.
Justenhoven C, Hamann U, Schubert F, Zapatka M, Pierl CB, Rabstein S, Selinski S, Mueller T, Ickstadt K, Gilbert M, Ko YD, Baisch C, Pesch B, Harth V, Bolt HM, Vollmert C, Illig T, Eils R, Dippon J, Brauch H (2008) Breast cancer a candidate gene approach across the estrogen metabolic pathway. Breast Cancer Res Treat 108:137–149CrossRefPubMed
57.
Zhang LN, Qian BY, Chen KX, Gu L (2008) Association between a genetic polymorphism in CYPl7 and sporadic breast cancer risk in Tianjin Women of Han Nationality. Zhong Guo Zhong Liu Lin Chuang 35:530–533
58.
Xie W, Feng MH, Wang HB, Chen JK, Cheng TT, Hu MB, Li CG, Zhou YF (2008) Single nucleotide polymorphism of estrogen metabolizing genes CYP17, CYP19 and breast cancer susceptibility. Chin J Gen Surg 23:540–542
59.
Ye Z, Parry JM (2002) The CYP17 MspA1 polymorphism and breast cancer risk a meta-analysis. Mutagenesis 17:119–126CrossRefPubMed
60.
Feigelson HS, McKean-Cowdin R, Henderson BE (2002) Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis 17:445–446CrossRefPubMed
61.
Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129CrossRef
62.
Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMed
63.
64.
Tobias A (1998) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8:15–17
65.
Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMed
66.
Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE (1997) A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 57:1063–1065PubMed
Metadata
Title
No association between CYP17 T-34C polymorphism and breast cancer risk: a meta-analysis involving 58,814 subjects
Authors
Lei Yao
Fang Fang
Qi Wu
Zhen Yang
Yang Zhong
Long Yu
Publication date
01-07-2010
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0679-4

Other articles of this Issue 1/2010

Breast Cancer Research and Treatment 1/2010 Go to the issue

Epidemiology

The functional promoter polymorphism (−842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger

Epidemiology

SULT1A1 R213H polymorphism and breast cancer risk: a meta-analysis based on 8,454 cases and 11,800 controls

Preclinical study

Induction of the small heat shock protein αB-crystallin by genotoxic stress is mediated by p53 and p73

Brief Report

Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers

Invited Commentary

Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer

Epidemiology

Transforming growth factor-β1 polymorphisms and breast cancer risk: a meta-analysis based on 27 case–control studies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits